<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03393806</url>
  </required_header>
  <id_info>
    <org_study_id>207972</org_study_id>
    <nct_id>NCT03393806</nct_id>
  </id_info>
  <brief_title>Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)</brief_title>
  <official_title>A Double Blind (Sponsor Open) Placebo-controlled, Stratified, Parallel Group Study to Evaluate the Efficacy and Safety of Repeat Doses of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is multicenter, double-blinded parallel group design, where participants with
      moderate to severe asthma with AFAD will be enrolled. Participants will receive three doses
      of 10 milligrams/kilogram (mg/kg) of GSK3772847 every 4 Weeks versus placebo along with
      standard of care. Participants will be randomized in 1:1 ratio to receive either 10 mg/kg
      GSK3772847 intravenously (IV) or matching placebo IV. Participants will receive study
      treatment on Week 0 (Day 1), Week 4 and Week 8. The total duration of the study will be 28
      Weeks and approximately 46 participants will be randomized.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 18, 2018</start_date>
  <completion_date type="Anticipated">July 2, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 9, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized in a 1:1 ratio to receive either 10 mg/kg GSK3772847 or matching placebo intravenously.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in blood eosinophils</measure>
    <time_frame>Baseline and up to Day 88</time_frame>
    <description>Blood samples will be collected at indicated time points for the assessment of eosinophil</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in fractional exhaled nitric oxide (FeNO)</measure>
    <time_frame>Baseline and up to Day 88</time_frame>
    <description>FeNO will be measured using a handheld electronic device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentrations of GSK3772847</measure>
    <time_frame>Day 1 post-end of infusion, Day 15, Pre-dose on Day 29, Pre-dose and post-dose on Day 57, Day 85 and Day 169</time_frame>
    <description>Blood samples will be collected at indicated time points for assessment of serum concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of free soluble suppressor of tumorigenicity 2 (ST2)</measure>
    <time_frame>Day 1 Pre and post-dose; Day 15; Day 29 Post dose; Day 57 pre and post dose; Day 85, Day 169</time_frame>
    <description>Blood samples will be collected at indicated time points to measure free soluble ST2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of total soluble ST2</measure>
    <time_frame>Day 1 Pre and post-dose; Day 15; Day 29 Post dose; Day 57 pre and post dose; Day 85, Day 169</time_frame>
    <description>Blood samples will be collected at indicated time points to measure total soluble ST2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with positive result of serum anti-GSK3772847 antibodies post dosing</measure>
    <time_frame>Up to Day 172</time_frame>
    <description>Blood samples will be collected at indicated time points and anti-GSK3772847 antibodies will be assessed using a tiered approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers of serum anti-GSK3772847 antibodies post dosing</measure>
    <time_frame>Up to Day 172</time_frame>
    <description>Blood samples will be collected at indicated time points and anti-GSK3772847 antibodies will be assessed using a tiered approach.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Asthma Control Questionnaire-5 (ACQ-5) absolute score at Weeks 2, 4, 8 and 12</measure>
    <time_frame>Baseline and at Weeks 2, 4, 8 and 12</time_frame>
    <description>ACQ-5 is a 5-item questionnaire that is a measure of the participant's asthma control. The five questions include about the frequency and/or severity of symptoms like nocturnal awakening, activity limitation, shortness of breath and wheeze. The score scales from zero (totally controlled) and 6 (severely uncontrolled)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Asthma Quality of Life Questionnaire (AQLQ) total and domain scores at Weeks 2, 4, 8 and 12</measure>
    <time_frame>Baseline and at Weeks 2, 4, 8 and 12</time_frame>
    <description>AQLQ is 32 items four domains questionnaire used for evaluation of impact of asthma treatments on the quality of life of participants. The scores are evaluated from 1 (total impairment) and 7 (no impairment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responders to ACQ-5</measure>
    <time_frame>Up to Day 88</time_frame>
    <description>ACQ-5 is a 5 question tool used to measure attributes of asthma control and the score ranges from 0 to 6 where 0 is no impairment/limitation and 6 is total impairment/limitation. A responder to ACQ-5 will be defined as a participant who has a decrease from Baseline in ACQ-5 score of 0.5 or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of responders to AQLQ</measure>
    <time_frame>Up to Day 88</time_frame>
    <description>AQLQ is a 32 items four domain questionnaire used to measure quality of life participants due to asthma treatment and the scores ranges from 1 to 7 where 1 indicates total impairment and 7 indicates no impairment. A responder to AQLQ will be defined as a participant who has an increase from Baseline in AQLQ score of 0.5 or more.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in forced expiratory volume in 1 second (FEV1)</measure>
    <time_frame>Up to Day 88</time_frame>
    <description>Spirometry assessment will include pre-bronchodilator FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in forced vital capacity (FVC)</measure>
    <time_frame>Up to Day 88</time_frame>
    <description>Spirometry assessment will include pre-bronchodilator FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment emergent adverse events (AE) and serious AEs (SAE)</measure>
    <time_frame>Up to Day 172</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose may result in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, congenital anomaly/birth defect or any other situation according to medical or scientific judgment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal hematology parameters</measure>
    <time_frame>Up to Day 172</time_frame>
    <description>Laboratory assessment for hematology parameters will include Platelet count, hemoglobin, Red blood cell (RBC) count, hematocrit, Red blood cell distribution width (RDW), RBC indices like mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC). White blood cell (WBC) count with differential will include neutrophils, lymphocytes, monocytes, eosinophils and basophils.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal clinical chemistry parameters</measure>
    <time_frame>Up to Day 172</time_frame>
    <description>Laboratory assessment for clinical chemistry parameters will include blood urea nitrogen (BUN), potassium, calcium, sodium, creatinine, non-fasting glucose, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline phosphate, Gamma-glutamyl transferase (GGT), albumin, phosphorus, carbon dioxide, total protein, creatine phosphokinase (CPK), total and direct bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal systolic blood pressure (SBP) and diastolic blood pressure (DBP)</measure>
    <time_frame>Up to Day 172</time_frame>
    <description>Blood pressure will be measured in supine position after 5 minutes rest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal heart rate</measure>
    <time_frame>Up to Day 172</time_frame>
    <description>Heart rate will be measured in supine position after 5 minutes rest</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal findings in Electrocardiogram (ECG)</measure>
    <time_frame>Up to Day 88</time_frame>
    <description>Single 12-lead ECG will be obtained using an ECG machine that automatically measures heart rate, PR, QRS, QT, and QT interval corrected for heart rate (QTc) and ventricular rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal 24-hour Holter findings</measure>
    <time_frame>Day 1</time_frame>
    <description>Holter assessment will be used for quantitative assessment of abnormal rhythm events. Holter monitor will be placed 30-60 minutes prior to dosing.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Participants receiving GSK3772847</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive GSK3772847 as IV infusion. Participants will receive three doses ( Day 1, Day 29 and Day 57) of GSK3772847 every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants receiving placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to receive matching placebo as IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3772847</intervention_name>
    <description>GSK3772847 will be available as 100 mg/vial, white to yellow, uniform lyophilized cake in a 5 milliliter (mL) clear glass vial with closure sealed by red metal and yellow overseal.</description>
    <arm_group_label>Participants receiving GSK3772847</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Commercially sourced sterile normal saline will be provided as Placebo</description>
    <arm_group_label>Participants receiving placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must be at least 18 years of age inclusive, at the time of signing the
             informed consent.

          -  Documented history of physician diagnosed moderate or severe asthma for &gt;=12 months
             based on Guidelines and treated with inhaled corticosteroid (ICS) and long-acting
             beta-2-agonist (LABA) for at least 4 months (&gt;=500 micrograms/day [Âµg/day])
             fluticasone propionate or equivalent as defined in the guidelines.

          -  Pre-bronchodilator FEV1 35-79% of predicted value for participant inclusive

          -  FeNO &gt;= 25 parts per billion (ppb) at Screening

          -  ACQ-5 score &gt;= 1.5 at Screening

          -  Blood eosinophil &gt;=300 cells/microliter at Screening

          -  Evidence of allergic fungal airway disease like Fungal sensitization to any of the
             fungi Aspergillus fumigatus, Penicillium chrysogenum (notatum) at screening measured
             by serum-specific Immunoglobulin (Ig) E test. A history of exacerbations with at least
             1 severe exacerbation (defined as requiring a minimum of 3 days of high-dose oral
             corticosteroids for asthma symptoms) in the previous 12 months.

          -  Body weight within 50-150 kilogram (kg)

          -  Both male and female gender. A female participant is eligible to participate if she is
             not pregnant not breastfeeding, Not a woman of childbearing potential (WOCBP) or A
             WOCBP who agrees to follow the contraceptive guidance during the treatment period and
             for at least 16 weeks after the last dose of study treatment.

          -  Capable of giving signed informed consent

        Exclusion Criteria:

          -  Historical diagnosis of cystic fibrosis

          -  Concurrent respiratory diseases: Presence of a known pre-existing, clinically
             important respiratory conditions (example pneumonia, pneumothorax, atelectasis
             segmental or larger, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic
             bronchitis, emphysema, chronic obstructive pulmonary disease, or other respiratory
             abnormalities) other than asthma or AFAD

          -  Has a history of chronic or recurrent non-pulmonary infectious disease or ongoing
             non-pulmonary infection including, but not limited to, chronic renal infection,
             chronic chest infection, recurrent urinary tract infection (example, recurrent
             pyelonephritis, chronic non-remitting cystitis), or open, draining skin wound or an
             ulcer

          -  Serious infection within 8 weeks of enrolment, including, but not limited to
             hepatitis, pneumonia, sepsis, or pyelonephritis; or has been hospitalized for an
             infection; or has been treated with IV antibiotics for an infection, within 8 weeks
             prior to the first administration of study drug.

          -  Evidence of poorly controlled chronic medical conditions other than asthma, example,
             participants with known, pre-existing, clinically significant endocrine, autoimmune,
             metabolic, neurological, renal, cardiovascular, gastrointestinal, hepatic, and
             hematological or any other system abnormalities that are uncontrolled with standard
             treatment.

          -  Cardiovascular disease: Clinically significant organic heart disease

          -  Participants with a diagnosis of malignancy or in the process of investigation for a
             malignancy. Participants with carcinoma that have not been in complete remission for
             at least 5 years. Participants who have had carcinoma in situ of the cervix, squamous
             cell carcinoma and basal cell carcinoma of the skin would not be excluded based on the
             5 year waiting period if the participant has been considered cured by treatment.

          -  Eosinophilic diseases: Other conditions that could lead to elevated eosinophil such as
             hyper-eosinophilic syndromes. Participants with a known, pre-existing parasitic
             infestation within 6 months prior to Screening (Visit 1)

          -  Prohibited medications is not permitted within the defined time intervals prior to
             Screening (Visit 1) and throughout the study.

          -  Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test
             result at screening or within 3 months prior to first dose of study treatment.

          -  A known immunodeficiency such as human immunodeficiency virus infection.

          -  Hypersensitivity: significant allergies to humanized monoclonal antibodies or biologic
             or to any components of the formulation used in this study

          -  Clinically significant multiple or severe drug allergies, intolerance to topical
             corticosteroids, or severe post-treatment hypersensitivity reactions (including, but
             not limited to, erythema multiforme major, linear Ig A dermatosis, toxic epidermal
             necrolysis, and exfoliative dermatitis).

          -  Clinically significant abnormality on 12-lead ECG assessment at screening (Visit 1).
             Site investigators will be provided with ECG over-read conducted by a centralized
             independent cardiologist, to assist in evaluation of participant eligibility.

          -  Sinus bradycardia &lt;45 beats per minute (bpm), sinus tachycardia &gt;= 110 bpm, multifocal
             atrial tachycardia (wandering atrial pacemaker with rate &gt;100bpm), evidence of Mobitz
             II second degree or third degree atrioventricular (AV) block, pathological Q waves
             (defined as wide [&gt;0.04 seconds] and deep [&gt;0.4 millivolts (mV) (4 millimeter [mm]
             with 10mm/mV setting)] or &gt;25% of the height of the corresponding R wave, providing
             the R wave was &gt;0.5mV [5mm with 10mm/mV setting], appearing in at least two contiguous
             leads, evidence of ventricular ectopic couplets, bigeminy, trigeminy or multifocal
             premature ventricular complexes, for participants without complete right bundle branch
             block: QTc for heart rate by Fridericia's formula QTc(F) &gt;= 450 millisecond (msec) or
             an ECG that is unsuitable for QT measurements, for participants with complete right
             bundle branch block: QTc(F) &gt;=480 msec or an ECG that is unsuitable for QT
             measurements, ST-T wave abnormalities, clinically significant conduction abnormalities
             and clinically significant arrhythmias.

          -  Smoking history: current smokers or former smokers with a smoking history &gt;= 10 pack
             years

          -  History of alcohol or illegal substance abuse within 2 years prior to Screening
             (Visit1).

          -  Participants at risk of non-compliance, or unable to comply with the study procedures.
             Participants who are unable to follow study instructions such as visit schedule and
             paper diary completion. Participants who have known evidence of lack of adherence to
             controller medication and/or ability to follow physician's recommendations. Any
             infirmity, disability, or geographic location that would limit compliance for
             scheduled visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edgbaston</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>January 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2018</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma Control Questionnaire</keyword>
  <keyword>Allergic fungal airway disease</keyword>
  <keyword>Asthma Quality of Life Questionnaire</keyword>
  <keyword>Holter monitoring</keyword>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

